Peregrine Ventures, an investment firm based in Or Yehuda, Israel, has quickly made a name for itself as a powerhouse in the global healthcare sector.
Recognized as Israel’s most active health tech investor by Startup Nation Central (SNC) on their Health Tech 2024 Map, the firm made 15 health tech investments last year alone.
This strong track record highlights their commitment to investing in transformative healthcare opportunities that make a real impact worldwide.
Investment Focus: A Diverse Approach Across the Healthcare Landscape
Peregrine Ventures manages a portfolio of approximately $600 million across various investment vehicles.
The firm invests in companies at every stage of development—from early pre-seed to later-stage ventures—ensuring it can support innovative startups throughout their growth journey.
In 2024, Peregrine Ventures made notable investments in companies like Variantyx, Insightec, Kahr Medical, and Cordio Medical, among many others.
These companies span a wide range of specialties, reflecting Peregrine’s diverse approach to health tech investing.
Core Investment Areas: Brain, Cardiovascular, and Oncology
Peregrine Ventures focuses on three primary pillars in healthcare: brain diseases and injuries, cardiovascular care, and oncology.
By building clusters of complementary technologies within these areas, the firm supports a range of approaches, including pharmaceuticals, medical devices, digital health solutions, and robotics.
Brain Health
In the brain health space, Peregrine’s portfolio features companies such as BrainQ, which is advancing a novel therapy to improve stroke recovery.
Other key investments include Endostream, which is developing minimally invasive devices for brain aneurysms, and Insightec, a leader in non-invasive surgical solutions for conditions like Parkinson’s disease and Essential Tremor.
Additionally, companies like Althea Medical and Magneto Thrombectomy Solutions are working to revolutionize clot removal technology and improve patient outcomes.
Cardiovascular Care
When it comes to cardiovascular health, Peregrine backs innovators like Restore Medical, which is tackling heart failure through non-valve restructuring.
Other investments include BioRefine, which is working on implant-free solutions for mitral and tricuspid valve repair, and Cordio Medical, a digital health company using speech analysis to help patients with congestive heart failure.
Ionara Bio is also part of the portfolio, advancing small molecules to treat heart failure and cardiomyopathies.
Oncology
In oncology, Peregrine supports both pharmaceutical companies like Kahr Medical and Nectin Therapeutics, as well as diagnostic and device innovators such as OncoRedox, Snipe Medical, and Magnisity.
These companies focus on areas such as liquid biopsy diagnostics and advanced lung cancer treatment, showcasing Peregrine’s commitment to advancing cancer care.
Expanding Horizons: Pulmonary Diseases and Neuromodulation
Looking ahead, Peregrine Ventures is broadening its focus to include pulmonary diseases and neuromodulation.
In particular, the firm is targeting neurodegenerative conditions like Alzheimer’s and Parkinson’s disease.
Through investments in cutting-edge therapeutic devices, Peregrine aims to make significant strides in treating these challenging conditions.
More Than Just Investment: Hands-On Support
Peregrine Ventures goes beyond just financial support.
The firm is actively involved in helping portfolio companies with team building, regulatory guidance, and strategic business planning.
Through its technology incubator, Incentive, operated in collaboration with Bristol Myers Squibb and Becton Dickinson, Peregrine provides early-stage companies with access to critical resources and multidisciplinary expertise.
This helps fuel their growth and drives innovation forward in the health tech space.
By combining strong financial backing with hands-on expertise, Peregrine Ventures continues to lead the way in health tech investment, making a lasting impact on the global healthcare landscape.